SCHEDULE 13G/A: Vivek Ramaswamy Discloses 11.16% Beneficial Ownership in Roivant Sciences Ltd.

Vivek Ramaswamy has filed an amended Schedule 13G, disclosing a beneficial ownership of 11.16% in Roivant Sciences Ltd., totaling 82,956,521 common shares as of December 31, 2024.

Summary

• Vivek Ramaswamy reported beneficial ownership of 82,956,521 common shares in Roivant Sciences Ltd. as of December 31, 2024.
• This ownership represents 11.16% of the company's common shares outstanding.
• The beneficially owned shares consist of 53,431,426 Restricted Stock Awards (RSAs) and 25,525,095 common shares underlying Options, as detailed in Item 4(a) of the filing.
• Mr. Ramaswamy holds sole voting and sole dispositive power over all 82,956,521 beneficially owned common shares.
• The percentage ownership calculation is based on an aggregate of 743,074,553 common shares issued and outstanding as of February 6, 2025.
• This aggregate includes 713,549,458 common shares disclosed in the Issuer's Form 10-Q for the quarterly period ended December 31, 2024, and 29,525,095 common shares underlying Options held by Mr. Ramaswamy that are subject to vesting and settlement within 60 days of December 31, 2024.
• An intrafamily transfer for estate planning purposes occurred after the close of the reporting period, as reported on a Form 4 filed on January 27, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant ownership stake by a key individual, which generally indicates continued alignment of interests. No negative information is presented.

Positives

• The filing provides transparency regarding a significant individual's substantial ownership stake in Roivant Sciences Ltd., which can indicate alignment of interests with other shareholders.
• The continued disclosure of a large insider holding may reinforce investor confidence in the company's long-term prospects.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future operations or financial performance.

Industry Context

This filing is a standard regulatory disclosure of a significant individual ownership stake and does not provide specific insights into broader industry trends or competitive dynamics beyond the fact that a key individual maintains a substantial position in a biotechnology/pharmaceutical company.

Comparison to Industry Standards

• This document is a beneficial ownership report (Schedule 13G) and does not contain financial or operational results that can be compared to industry benchmarks or specific comparable companies/projects. It solely reports the ownership stake of an individual.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant insider's ownership, potentially reinforcing confidence due to alignment of interests.
• Employees, Customers, Suppliers, Creditors: No direct impact mentioned in this ownership disclosure.

Key Dates

Keywords

Roivant Sciences, Vivek Ramaswamy, Beneficial Ownership, Schedule 13G, SEC Filing, Common Shares, Insider Ownership, G76279101